Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.2 USD | -1.79% | -5.98% | +76.00% |
Apr. 16 | Lexaria Obtains Ethics Review Board Approval to Start New GLP-1 Study | MT |
Apr. 16 | Lexaria Bioscience Corp. Receives Ethics Review Board Approval to Begin New GLP-1 Study | CI |
Financials (USD)
Sales 2024 * | 482K | Sales 2025 * | 488K | Capitalization | 28.35M |
---|---|---|---|---|---|
Net income 2024 * | -6M | Net income 2025 * | -7M | EV / Sales 2024 * | 58.9 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 58.2 x |
P/E ratio 2024 * |
-4.11
x | P/E ratio 2025 * |
-4.44
x | Employees | 5 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 91.42% |
1 day | -1.79% | ||
1 week | -5.98% | ||
Current month | -39.39% | ||
1 month | -36.60% | ||
3 months | +40.13% | ||
6 months | +81.82% | ||
Current year | +76.00% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
John Docherty
PSD | President | 53 | 15-04-14 |
George Jurcic
IRC | Investor Relations Contact | - | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 62 | 06-10-25 | |
Nicholas Baxter
BRD | Director/Board Member | 70 | 11-07-07 |
Albert Reese
BRD | Director/Board Member | 74 | 21-01-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-24 | 2.2 | -1.79% | 98,910 |
24-04-23 | 2.24 | -1.10% | 53,986 |
24-04-22 | 2.265 | +2.95% | 34,458 |
24-04-19 | 2.2 | -2.22% | 61,647 |
24-04-18 | 2.25 | -3.85% | 124,708 |
Delayed Quote Nasdaq, April 24, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+76.00% | 28.35M | |
+25.61% | 660B | |
+25.87% | 562B | |
-5.24% | 358B | |
+16.49% | 322B | |
+8.28% | 297B | |
+7.09% | 219B | |
-9.12% | 196B | |
+5.01% | 199B | |
-8.75% | 149B |
- Stock Market
- Equities
- LEXX Stock